Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Invested Capital (2016 - 2026)

Viridian Therapeutics, Inc.\DE has reported Invested Capital over the past 12 years, most recently at $772.1 million for Q4 2025.

  • Quarterly results put Invested Capital at $772.1 million for Q4 2025, up 11.54% from a year ago — trailing twelve months through Dec 2025 was $772.1 million (up 11.54% YoY), and the annual figure for FY2025 was $772.1 million, up 11.54%.
  • Invested Capital for Q4 2025 was $772.1 million at Viridian Therapeutics, Inc.\DE, up from $523.9 million in the prior quarter.
  • Over the last five years, Invested Capital for VRDN hit a ceiling of $772.1 million in Q4 2025 and a floor of $98.9 million in Q2 2021.
  • Median Invested Capital over the past 5 years was $406.7 million (2022), compared with a mean of $409.8 million.
  • Biggest five-year swings in Invested Capital: soared 872.3% in 2021 and later decreased 28.04% in 2025.
  • Viridian Therapeutics, Inc.\DE's Invested Capital stood at $187.7 million in 2021, then surged by 112.93% to $399.7 million in 2022, then grew by 15.64% to $462.2 million in 2023, then surged by 49.76% to $692.2 million in 2024, then increased by 11.54% to $772.1 million in 2025.
  • The last three reported values for Invested Capital were $772.1 million (Q4 2025), $523.9 million (Q3 2025), and $536.0 million (Q2 2025) per Business Quant data.